Herishanu et al. demonstrated that CLL cells have an upregulated BCR signaling signature based on gene expression and clinically, the BCR can be targeted by phosphoinositide 3-kinase (PI3K) or Bruton’s tyrosine kinase (BTK) inhibitors [19,20]. Here, BCR is linked to B-cell chronic lymphocytic leukemia.